checkAd

     317  0 Kommentare Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs - Seite 3

    Investor Contact:

    Lesen Sie auch

    Samuel Fisch
    Executive Director, Investor Relations and Corporate Communications
    Email: veruinvestor@verupharma.com 


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs - Seite 3 MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress …